VTCN1 (b7-h4) IgC domain induced T reg

Description:

A Method for Inducing iTreg Cells 

 Sanford Tech ID: 0031-01

 

INVENTION SUMMARY

 

0031-01 is a method by which induced T regulatory

cells can be produced from naïve CD4+CD25- T cells

and/or naïve CD8+CD25- cells in vitro with a certain

engineered polypeptide. Taking advantage of Tregs

has been complicated by an inability to expand and

characterize this minor T cell subset, a population

of cells reduced even further in autoimmune-prone

patients. The methods of the present invention provide

a significant improvement in the ability to generate

and expand iTregs for clinical use.

 

VALUE PROPOSITION

 

• May allow for a smaller blood volume to be

harvested from children being treated for

type 1 diabetes.

• May enable faster and more efficient Treg

isolation and expansion.

 

MARKET OPPORTUNITY

 

This technology can provide a strategic advantage for

companies who have an already existing therapeutic

Treg product.

 

INTELLECTUAL PROPERTY

 

A non-provisional patent application has been filed.

 

DEVELOPMENT STATUS

 

In vitro Treg induction proof of concept is complete.

 

Patent Information:
Category(s):
Biotherapeutic
For Information, Contact:
Rick Evans
Research Project Manager
Sanford Health
rick.evans@sanfordhealth.org
Inventors:
Alexei Savinov
Ilian Radichev
Christina Amatya
Keywords: